Logiscreen

Charles River Laboratories International Inc

$240.43
Market Cap 11.84B
ROE -5.7%
Gross Margin 29.6%
Debt/Equity 1.0
Current Ratio 1.4
Revenue QoQ 1.2%
EPS QoQ -1.6%
F-Score 4

About

Charles River Laboratories International, Inc. is a global provider of solutions, which accelerate the early-stage drug discovery and development process. The focus of its business is in vivo biology; its portfolio includes research models and services required to enable in vivo drug discovery and development. The Company operates in two segments: Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company has been supplying research models to the drug development industry. The Company is engaged in the production and sale of rodent research model strains, principally genetically and microbiologically defined purpose-bred rats and mice. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. In August 2012, the Company acquired Accugenix, Inc. In January 2013, the Company acquired 75% ownership of Vital River.

Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-62.23
vs median 36.93
P/B
3.91
vs median 2.32
ROE
-0.06
vs median 0.09

Lower quality - review fundamentals carefully

Large-cap company with established market presence

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics